This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Compared to some of the previous years in the market, 2018 so far has been akin to the proverbial paint drying. While the S&P 500 did eke out a small 2.6% gain in the first half, it took a solid two-month lift from the secondary lows in April to get there. One thing is for sure, the mega-cap stocks in the index paved the way, and there is a good chance that could remain the case the rest of the year.
MNST KO DWDP
July 17, 2018: Markets opened lower Tuesday but equities quickly reversed course and muddled through the rest of the day with some gains. Fed chairman Jerome Powell said the central bank would make no sudden moves on monetary policy, but that rate increases would continue “gradually.” The materials sector was the day’s big gainer and real estate was posted the biggest decline. Three Dow stocks reported second-quarter earnings this morning: Johnson & Johnson, Goldman Sachs, and UnitedHealth.
JNJ MSFT UTX DWDP
The Singaporean state investor, whose S$308 billion portfolio (US$226 billion) includes stakes in companies such as Alibaba Group Holding Ltd, is still betting on the U.S., even as it grows more circumspect in deploying capital amid trade tensions and an increased likelihood of a global economic slowdown.
JBK GSC GS.PRICL TFG GS.PRB GS.PRA GOOG GSJ DWDP GS.PRJ GS.PRI GS BABA GLSSP GOOGL GS.PRD BOE GS.PRC GJS GS.PRN BA GS.PRK
All the Wall Street firms that we follow here at 24/7 Wall St. keep a list for their institutional and retail clients of high-conviction stock picks. These are generally the companies they not only like on a longer term basis, but stocks that usually have big upside to the assigned target price.
DLTR NOW AVGO BRCM DWDP DIS
July 11, 2018: Markets opened lower Wednesday with rising concerns over the effects of the trade war and Trump’s comments at the opening of the NATO summit meeting. Utilities was the only sector to post even a small increase while energy and basic materials were the day’s big losers.
CATR CAT BOE CVX BA DWDP
But recently, the equity research team at Goldman compiled a list of stocks within the company’s coverage universe that have the most potential upside to their price targets. The list is long (about 40 stocks), and Goldman pegs all of them as having roughly 30% or more upside to their price target.
LRCX CAT RCL NVDA MAR.WI CFIN NOC TSNU IP JEC CIWV TSN NCLH SCHW.PRBCL TDG INPAP DWDP CFG MAR SCHW MU BWA HRS WRK DE
23 of 30 Dow Industrial Index stocks were tagged as "safer" for dividends because they showed positive 1-year returns and free cash flow yields greater than their dividend yields as of 7/5/18.
MTSI PG TRV CAT WBA UTX DWDP VZA JNJ CVX CSCO VZ BA INTC PFE MCD MMM
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
GM.WS.A GM.WS.B GM.WS.C GM GM.WSB DWDP
30 Dow stocks represent nine of 11 sectors. Dow Tracks Utilities as a separate index and omits real estate. Broker target-estimated net gains ranged from 16.5% to 27.3%.
CAT XOM WBA GS.PRB GS.PRA VZA GS GLSSP CSCO INTC MCD IBM JBK GSC GS.PRICL TFG UTX DWDP GSJ GS.PRJ GS.PRI JNJ GS.PRD CVX GS.PRC VZ GJS GS.PRN PFE GS.PRK
July 10, 2018: Markets opened opened higher again Tuesday although gains are muted compared to both Friday and Monday. Second-quarter earnings begin in earnest Friday with several big financials posting results and investors appear to be positioning themselves for the expected good news. Defensive sectors carried the day with consumer staples and utilities posting decent gains.
PG BOE BA DWDP WMT
Regardless of what hits the market, nothing seems to be big enough to knock it back down in a big way. While the S&P 500 is up for the year, most of the market is fully valued on a historical basis. In fact, the current forward price to earnings for the S&P 500 is at 16.1 times earnings, and that is exactly the 25-year figure. The Shiller price-to-earnings figure is currently at 32.1 times earnings, versus a 25-year figure of 26.
MRVL IGT INTC DWDP
WASHINGTON (AP) — For 37 mostly female farm-workers in California's Central Valley, U.S. policy under Environmental Protection Agency chief Scott Pruitt became personal not long after sunup one day in May 2017.
A three-year U.S. Securities and Exchange Commission investigation found that Dow Chemical failed to properly disclose around US$3 million in perks for former Chief Executive Andrew Liveris, ranging from personal use of company aircraft to sporting events and dues Dow paid to a charity Liveris chaired.
NEW YORK (Reuters) - A three-year U.S. Securities and Exchange Commission investigation found that Dow Chemical failed to properly disclose around $3 million in perks for former Chief Executive Andrew Liveris, ranging from personal use of company aircraft to sporting events and dues Dow paid to a charity Liveris chaired.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET